Targeting the S and G2 checkpoint to treat cancer

详细信息	查看全文 | 推荐本文 |

• 作者：Tao Chen ; Peter A. Stephens ; Fiona K. Middleton ; Nicola J. Curtin ; ^{nicola.curtin@newcastle.ac.uk} ; ^{n.j.curtin@newcastle.ac.uk}
• 刊名：Drug Discovery Today
• 出版年：2012
• 期刊代码：29_13596446
• 类别：imm
• 出版时间：March, 2012
• 卷：17
• 期：5-6
• 页码：194-202
• 文件大小：255 K

摘要

Cell survival following DNA damage depends on activating checkpoints to arrest proliferation. Most cancer cells have dysregulated G1 checkpoints making them dependent on their S and G2 checkpoints, which are activated by ATR/Chk1 signalling. Thus, inhibiting ATR or Chk1 should selectively sensitise cancer cells to DNA damage. Genetic inactivation of ATR and Chk1 abrogates cell cycle arrest and enhances cytotoxicity following exposure to DNA-damaging agents. Similar effects were seen with small-molecule Chk1 inhibitors in preclinical studies, and clinical trial data are starting to emerge. Recently, potent ATR inhibitors have been identified that also sensitise cancer cells in vitro. ATR and Chk1 inhibitors might also cause 鈥榮ynthetic lethality鈥?in tumour cells defective in defined DNA repair pathways.